- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Texas Medical Center First to Implant Novel Defibrillation Lead
The world's smallest, catheter-delivered defibrillation lead allows for precise delivery and placement.
Feb. 1, 2026 at 7:31pm
Got story updates? Submit your updates here. ›
Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center in Austin have become the first in the U.S. to implant an FDA-approved novel defibrillation lead, a specialized wire that connects an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT-D) device to the heart to correct abnormal rhythms. The new lead is the world's smallest, catheter-delivered defibrillation lead, enabling more precise placement.
Why it matters
This new technology represents an advancement in the treatment of cardiac arrhythmias, which affect an estimated 12.1 million Americans and can lead to sudden cardiac arrest. The smaller, more precisely delivered lead may help reduce complications associated with existing larger defibrillation leads.
The details
The first procedure using the new lead was performed on January 7 by TCAI electrophysiologists Robert Canby, M.D., and Amin Al-Ahmad, M.D. Dr. Canby also participated in the clinical trial that led to the lead's FDA approval. The new lead senses the heartbeat and transmits signals to the implanted device, which then delivers therapy to interrupt abnormal heart rhythms.
- The first procedure using the new lead was performed on January 7, 2026.
- According to the Journal of the American Heart Association, an estimated 12.1 million people in the U.S. are expected to have atrial fibrillation by 2030.
The players
Texas Cardiac Arrhythmia Institute (TCAI)
A state-of-the-art Electrophysiology Center at St. David's Medical Center in Austin, Texas, that includes six labs equipped with advanced technology and is led by a team of esteemed cardiac electrophysiologists.
Robert Canby, M.D.
A clinical cardiac electrophysiologist at TCAI who performed the first procedure using the new defibrillation lead and also participated in the clinical trial that led to its FDA approval.
Amin Al-Ahmad, M.D.
A clinical cardiac electrophysiologist at TCAI who performed the first procedure using the new defibrillation lead.
Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C.
A cardiac electrophysiologist and the executive medical director of TCAI.
What they’re saying
“When treating patients, safety and efficacy are paramount, and this novel technology allows us to achieve both with greater precision.”
— Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., Cardiac electrophysiologist and executive medical director of TCAI (PR Newswire)
The takeaway
This milestone for the Texas Cardiac Arrhythmia Institute demonstrates the continued pursuit of innovative medical technologies that can improve patient outcomes and access to life-saving cardiac care.
